Answers are grounded in this paper and cite their sources.
The Down syndrome candidate region 1 gene (DSCR1) can be expressed as four isoforms, one of which is the well-studied isoform 4 (DSCR1-4) that is induced by VEGF-A165 to provide a negative feedback loop in the VEGF-A165-induced angiogenesis. We reported previously that another DSCR1 isoform, DSCR1-1L, was also up-regulated by VEGF-A165 in cultured endothelial cells and in several in vivo models of pathological angiogenesis and that different from DSCR1-4, DSCR1-1L overexpression alone induced cultured endothelial cell proliferation and promoted angiogenesis in Matrigel assays. It was reported recently that tumor growth was greatly repressed in DSCR1 knock-out mice. Although DSCR1-4 transcription was primarily regulated by NFAT, the mechanism regulating DSCR1-1L expression was still unknown. We developed human DSCR1-1L promoter-driven luciferase system and found that deletion of a putative conserved M-CAT site located 1426-bp upstream of the translation start site blunted promoter activity. We further showed that knockdown of TEF3, not other members of TEF family inhibited VEGF-A165-induced DSCR1-1L expression. We also demonstrated that TEF3 directly interacted with the putative M-CAT site in the DSCR1-1L promoter in vitro and in vivo. Finally, overexpression of TEF3 isoform 1, not isoform 3, in HUVEC was sufficient to induce DSCR1-1L expression even in the absence of VEGF-A165 stimulation. Taken together, we elucidated a novel function of transcriptional factor TEF3. TEF3 was required for DSCR1-1L expression through binding to the M-CAT site in its promoter and could be an attractive target for anti-angiogenesis therapy. The Down syndrome candidate region 1 gene (DSCR1) can be expressed as four isoforms, one of which is the well-studied isoform 4 (DSCR1-4) that is induced by VEGF-A165 to provide a negative feedback loop in the VEGF-A165-induced angiogenesis. We reported previously that another DSCR1 isoform, DSCR1-1L, was also up-regulated by VEGF-A165 in cultured endothelial cells and in several in vivo models of pathological angiogenesis and that different from DSCR1-4, DSCR1-1L overexpression alone induced cultured endothelial cell proliferation and promoted angiogenesis in Matrigel assays. It was reported recently that tumor growth was greatly repressed in DSCR1 knock-out mice. Although DSCR1-4 transcription was primarily regulated by NFAT, the mechanism regulating DSCR1-1L expression was still unknown. We developed human DSCR1-1L promoter-driven luciferase system and found that deletion of a putative conserved M-CAT site located 1426-bp upstream of the translation start site blunted promoter activity. We further showed that knockdown of TEF3, not other members of TEF family inhibited VEGF-A165-induced DSCR1-1L expression. We also demonstrated that TEF3 directly interacted with the putative M-CAT site in the DSCR1-1L promoter in vitro and in vivo. Finally, overexpression of TEF3 isoform 1, not isoform 3, in HUVEC was sufficient to induce DSCR1-1L expression even in the absence of VEGF-A165 stimulation. Taken together, we elucidated a novel function of transcriptional factor TEF3. TEF3 was required for DSCR1-1L expression through binding to the M-CAT site in its promoter and could be an attractive target for anti-angiogenesis therapy. Down syndrome candidate region 1 (DSCR1) 2The abbreviations used are: DSCR, Down syndrome candidate region; VEGF-A165, vascular endothelial growth factor-A165; M-CAT, muscle-specific CAT element; TEF, transcription enhancer factor; siTEF, TEF-specific siRNA; siNeg, control siRNA; FTEF, FLAG-fused TEF; HUVEC, human umbilical vein endothelial cells; HMVEC, human microdermal vascular endothelial cells; EOMA, hemangioma cells; EMSA, electrophoresis mobility shift assays; PBS, phosphate-buffered saline; UTR, untranslated region; ChiP, chromatin immunoprecipitation assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. is one of more than 50 genes present in the portion of trisomy 21, the chromosomal abnormality responsible for Down syndrome (1Hassold T.J. Jacobs P.A. Annu. Rev. Genet. 1984; 18: 69-97Crossref PubMed Scopus (557) Google Scholar, 2Fuentes J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, 3Fuentes J.J. Pritchard M.A. Planas A.M. Bosch A. Ferrer I. Estivill X. Hum. Mol. Genet. 1995; 4: 1935-1944Crossref PubMed Scopus (225) Google Scholar). DSCR1 is identical to MCIP1 (modulatory calcineurin-interacting protein) (4Rothermel B. Vega R.B. Yang J. Wu H. Bassel-Duby R. Williams R.S. J. Biol. Chem. 2000; 275: 8719-8725Abstract Full Text Full Text PDF PubMed Scopus (372) Google Scholar). It is homologous to Adapt78, an oxidant stress-inducible gene in hamsters (5Crawford D.R. Leahy K.P. Abramova N. Lan L. Wang Y. Davies K.J. Arch. Biochem. Biophys. 1997; 342: 6-12Crossref PubMed Scopus (119) Google Scholar, 6Leahy K.P. Davies K.J. Dull M. Kort J.J. Lawrence K.W. Crawford D.R. Arch. Biochem. Biophys. 1999; 368: 67-74Crossref PubMed Scopus (39) Google Scholar, 7Ermak G. Morgan T.E. Davies K.J. J. Biol. Chem. 2001; 276: 38787-38794Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar) and also to Rcn1/nebula in Drosophila (8Gorlach J. Fox D.S. Cutler N.S. Cox G.M. Perfect J.R. Heitman J. EMBO J. 2000; 19: 3618-3629Crossref PubMed Scopus (151) Google Scholar). Down syndrome is a major cause of mental retardation and is also associated with various cardiac and gastrointestinal anomalies, immune system defects, and Alzeimer disease. Down syndrome patients have increased risks of certain malignancies (leukemia, germ cell tumors) but an extremely low incidence of many solid tumors, particularly breast cancer (9Hasle H. Lancet Oncol. 2001; 2: 429-436Abstract Full Text Full Text PDF PubMed Scopus (224) Google Scholar, 10Smucker J.D. Roth L.M. Sutton G.P. Hurteau J.A. Gynecol. Oncol. 1999; 74: 512-514Abstract Full Text PDF PubMed Scopus (14) Google Scholar). On the other hand, clinically aggressive ovarian carcinomas often have trisomy of chromosome 21, whereas certain other solid tumors have deletions of this chromosome. Together these and other data suggest that genes such as DSCR1 that are triplicated in Down syndrome may play important roles in tumorigenesis (11Faruqi S.A. Noumoff M.J. Deger R.B. Jalal S.M. Antoniades K. Cancer Genet. Cytogenet. 2002; 138: 165-168Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar, 12Verhest, A., Nedoszytko, B., Noel, J., Simon, P., and Limon, J. (1991) Fourth International Workshop on Chromosomes in solid Tumors, Abstract B24Google Scholar). Interest in DSCR1 has recently been sparked by several reports indicating that it is up-regulated in cultured vascular endothelial cells by VEGF-A165 and further that it provides a negative feedback loop that inhibits VEGF-A165-induced angiogenesis (13Liu D. Jia H. Holmes D.I. Stannard A. Zachary I. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2002-2007Crossref PubMed Scopus (141) Google Scholar, 14Minami T. Horiuchi K. Miura M. Abid R. Takabe W. Kohro T. Ge X. Aburatani H. Hamakubo T. Kodama T. Aird J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Biochem. Biophys. PubMed Scopus Google Scholar, G. Yang D. R. N. PubMed Scopus Google Scholar). the was on the of one DSCR1 isoform, isoform 4 The DSCR1 gene is of the four of which can as start that with to four different J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google Scholar). 1 was to a J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google but by L. A. J.J. Estivill X. M. Biochem. J. 2003; PubMed Scopus Google Scholar) a start site further upstream that an is not it a start J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google Scholar). the control of a different promoter from that regulating J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google a that a DSCR1 The several DSCR1 have different expression and different and J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google Scholar). four are expressed in and J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google Scholar). 1 has also been in and isoform 4 in and J.J. Pritchard M.A. Estivill X. Genomics. 1997; 44: 358-361Crossref PubMed Scopus (166) Google Scholar, G. Davies K.J. J. 2002; PubMed Scopus Google Scholar). DSCR1-1L has been found to play a cell (5Crawford D.R. Leahy K.P. Abramova N. Lan L. Wang Y. Davies K.J. Arch. Biochem. Biophys. 1997; 342: 6-12Crossref PubMed Scopus (119) Google Scholar, 6Leahy K.P. Davies K.J. Dull M. Kort J.J. Lawrence K.W. Crawford D.R. Arch. Biochem. Biophys. 1999; 368: 67-74Crossref PubMed Scopus (39) Google Scholar, 7Ermak G. Morgan T.E. Davies K.J. J. Biol. Chem. 2001; 276: 38787-38794Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar). to angiogenesis (13Liu D. Jia H. Holmes D.I. Stannard A. Zachary I. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2002-2007Crossref PubMed Scopus (141) Google Scholar, 14Minami T. Horiuchi K. Miura M. Abid R. Takabe W. Kohro T. Ge X. Aburatani H. Hamakubo T. Kodama T. Aird J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Biochem. Biophys. PubMed Scopus Google Scholar, G. Yang D. R. N. PubMed Scopus Google DSCR1-4 an in cardiac and J.D. J.R. B. J. J. Full Text Full Text PDF PubMed Scopus Google Scholar, A. K.J. N. 1999; PubMed Scopus Google Scholar, Wu M.J. T. T. 1999; PubMed Scopus Google Scholar). we reported that DSCR1-1L, DSCR1-4, was up-regulated by VEGF-A165 in cultured endothelial cells and also in several of pathological angiogenesis in vivo L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). DSCR1-1L was also expressed in the of human ovarian but not in the tumor cells in the of L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). the of DSCR1-1L in angiogenesis to of DSCR1-4 L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). a novel of the Matrigel we found that overexpression of DSCR1-1L promoted endothelial cell proliferation in vitro and angiogenesis in whereas a data that and have and on VEGF-A165-induced angiogenesis L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). it was reported that tumor growth was greatly repressed in DSCR1 knock-out DSCR1 M.J. A. A. Cancer Full Text Full Text PDF PubMed Scopus Google Scholar). DSCR1-1L and the that DSCR1-1L expression are for cancer therapy. It was that VEGF-A165-induced DSCR1-4 expression was by the in the DSCR1-4 promoter that was located in its J.J. L. T.J. K.W. M. Estivill X. Hum. Mol. Genet. 2000; PubMed Google Scholar). the that DSCR1-1L has not been the mechanism that DSCR1-1L expression in we a human DSCR1-1L promoter-driven luciferase to the mechanism of DSCR1-1L expression. and from human DSCR1-1L was from was from to was from TEF3 was developed previously Wu G. Wu J. J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). HUVEC cultured and with various as previously H. D. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar). cells and cells cultured in with and to a by the on the of and in in and for with with for of with PBS, for 1 with with PBS, with the for and with to for and of DSCR1-1L and the DSCR1-1L the human promoter was from a HUVEC by with a with and with The with and and the The of the promoter was by and this was to the translation start site is in the DSCR1-1L The used to deletion of which with and in the and and and and and The for the deletion The was The M-CAT was the of M-CAT and The was and cells in the of cells with and control luciferase with of directly to 50 of and and for promoter and to another 50 and and and for the was to cells and in the absence of for with and with of of cells HUVEC in cells with and control luciferase with of was directly to 50 of and for and to the and for and to cells with of cells with VEGF-A165 for with PBS, and with of cells was and to control luciferase to the of and with the and in of for on was for 1 and 4 for The as The that was with to the The was in of for on and 4 for The was used as by this than and The was with a with of M-CAT and with as in the was a the with and of putative in a 50 50 for The by electrophoresis on a 4 in for The to in for 1 4 and to 1 to the to the of was in with the with and 1 in the the with TEF3, and in the was from with for TEF3, and was as G. Davies K.J. J. 2002; PubMed Scopus Google Scholar). as a control for on The used are and and and and and and of TEF3 and by from HUVEC with in and of TEF3, The to and to and to with and and in HUVEC as previously H. D. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar). with the from and expressed in The and immunoprecipitation to the HUVEC and with and to immunoprecipitation with an TEF3, as a control 4 The chromosomal in the was with in and 1 and to with the and The to the of the putative M-CAT binding site on the portion of the The immunoprecipitation as chromatin are expressed on as the The was used to of was to be of DSCR1-1L in we reported that DSCR1-1L was expressed in the vascular of ovarian cancer not in tumor cells by L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). the tumor expression of also in other tumors, we the expression in human cancer by DSCR1-1L was expressed in the tumor vascular but not in the tumor in We further these by with from human cancer in DSCR1-1L was also expressed in human microdermal vascular endothelial cells in to HUVEC L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google but not in human cells hemangioma endothelial tumor to of that cause and growth N. A. J.A. 2003; PubMed Scopus Google we also DSCR1-1L was expressed in the that DSCR1-1L was expressed in the hemangioma cells data demonstrated that DSCR1 was expressed in endothelial not in cancer of a M-CAT in the DSCR1-1L in was reported that DSCR1-1L and DSCR1-4 of 1, and and expression of DSCR1-4 was regulated by the Biochem. Biophys. PubMed Scopus Google Scholar, B. G. T. A. PubMed Scopus Google Scholar, M. Y. Arch. Biochem. Biophys. PubMed Scopus Google Scholar, M. M. K. I. Y. J. Vasc. PubMed Scopus Google Scholar, J. Biol. PubMed Scopus Google Scholar, T. Horiuchi K. Miura M. Abid Takabe W. N. Kohro T. Ge X. Aburatani H. Hamakubo T. Kodama T. Aird J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). The promoter regulating DSCR1-4 was found in the 4 and several binding J.J. L. T.J. K.W. M. Estivill X. Hum. Mol. Genet. 2000; PubMed Google Scholar). DSCR1-4, DSCR1-1L is not to be induced through the (13Liu D. Jia H. Holmes D.I. Stannard A. Zachary I. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2002-2007Crossref PubMed Scopus (141) Google Scholar, Biochem. Biophys. PubMed Scopus Google Scholar, G. Yang D. R. N. PubMed Scopus Google Scholar, T. Horiuchi K. Miura M. Abid Takabe W. N. Kohro T. Ge X. Aburatani H. Hamakubo T. Kodama T. Aird J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). we the DSCR1-1L as The DSCR1-1L promoter was in hemangioma cells to be than HUVEC and expressed of DSCR1-1L as in cells with the with an control luciferase The DSCR1-1L promoter in cell was and to control luciferase for in the DSCR1-1L promoter induced luciferase We several deletion of the promoter as in The data in that was a major putative region from to We further the region and found putative binding the region of the promoter and luciferase was in showed that the deletion of a a putative M-CAT site from to of the DSCR1-1L promoter further which this region was we another deletion the M-CAT site with of cells in of DSCR1-1L promoter that the M-CAT site the further the of the M-CAT we the of the M-CAT site upstream of a promoter luciferase that the showed that the M-CAT site increased the promoter of the M-CAT in the DSCR1-1L for VEGF-A165-induced DSCR1-1L in the M-CAT site was required for DSCR1-1L promoter in HUVEC with the DSCR1-1L promoter M-CAT deletion in promoter and control promoter and with VEGF-A165 for in of DSCR1-1L promoter this VEGF-A165-induced promoter was in the The by the site was increased in to VEGF-A165 VEGF-A165 the of a with the M-CAT further M-CAT associated with in HUVEC with VEGF-A165 stimulation. from HUVEC with VEGF-A165 for and and to mobility shift with in was one in the absence of VEGF-A165 VEGF-A165 a was by and 3, and further the of this we and of and in the binding The data showed that of the shift of the binding and but the not and indicating that the binding was was in cells not of TEF3, not TEF for VEGF-A165-induced DSCR1-1L CAT is a conserved by TEF family K.J. Genet. PubMed Scopus Google Scholar). are 4 members of this family in which a identical binding A. Google Scholar, Full Text PDF PubMed Scopus Google Scholar). The for family transcription is conserved it was not TEF family members in VEGF-A165 which TEF family members a in DSCR1-1L promoter we which TEF family members expressed in HUVEC by with from in of four TEF family members expressed in HUVEC of the TEF family members expressed in HUVEC, we developed for TEF family TEF3 and We the of these for TEF family members and on DSCR1-1L expression. from HUVEC with the in and control to with TEF3, and in the in inhibited the expression of TEF that inhibited the expression of TEF3 4 The to with an We found that it was not that inhibited DSCR1-1L expression inhibited the expression of The showed the control with an We the of on DSCR1-1L expression. HUVEC with and negative to with an TEF3. in expression of inhibited the expression of TEF3, expression of alone in with inhibited the expression of TEF3 The with an expression of inhibited the expression of DSCR1-1L, expression of alone in with inhibited the expression of DSCR1-1L We to TEF3 was required for VEGF-A165-induced the of the M-CAT transcriptional from HUVEC that with TEF as to in the induced by VEGF-A165 was inhibited by expression of not by and by also that expression of and greatly inhibited the VEGF-A165-induced with M-CAT TEF3 with M-CAT in and in further that TEF3 may be the major in the induced by VEGF-A165, we by of TEF3 in the binding We found that TEF3 not the control other TEF family members the VEGF-A165-induced M-CAT the TEF3 also the an other than TEF family members in HUVEC with TEF3 by TEF3, not other family to the M-CAT site in the DSCR1-1L promoter in we assays. HUVEC with VEGF-A165 as with and to immunoprecipitation with TEF3 as a The chromosomal in the was and to The to the to the putative M-CAT binding site on the in a was in the with an TEF3, not with other control data that TEF3 directly interacted with the M-CAT in the DSCR1-1L promoter to VEGF-A165-induced DSCR1-1L expression. TEF3 1 DSCR1-1L TEF3 have been reported in different cells B. T.J. Davies Y. B. Y. T. PubMed Scopus Google Scholar, J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, J.J. J.A. I. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, J. D. Genomics. PubMed Scopus Google Scholar). it was not which are expressed in We the TEF3 from the from HUVEC by the in the region and region of TEF3 we the TEF3 isoform 1 and The to the in the and a expression which H. D. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar). The these genes used to in and in HUVEC The by with the data that not up-regulated DSCR1-1L expression have that angiogenesis and its associated play roles in tumor VEGF-A165 is the important in tumor angiogenesis. an that VEGF-A165, has in several of human has a of it is to the that play a in tumor but not in vascular that Down syndrome candidate region 1 isoform was up-regulated by VEGF-A165 in cultured endothelial cells and in several of angiogenesis in vivo L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). VEGF-A165-induced endothelial cell proliferation and angiogenesis was greatly inhibited by the expression of DSCR1-1L with L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). M.J. A. A. Cancer Full Text Full Text PDF PubMed Scopus Google Scholar) reported that tumor growth was greatly repressed in DSCR1 knock-out DSCR1 isoforms, indicating the of this family of in we found recently that DSCR1-1L was expressed in tumor vascular not in vascular of human ovarian cancer L. D. X. J.A. H. Mol. Cancer 4: PubMed Scopus Google Scholar). present further showed that DSCR1-1L was expressed in tumor of human not in tumor DSCR1-1L may a and target for tumor therapy. of the of DSCR1-1L in tumor of the mechanism responsible for DSCR1-1L in tumor the of the DSCR1 isoform is not to its gene present the one to this gene is regulated in DSCR1-4, DSCR1-1L is not to be induced through the (13Liu D. Jia H. Holmes D.I. Stannard A. Zachary I. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2002-2007Crossref PubMed Scopus (141) Google Scholar, 14Minami T. Horiuchi K. Miura M. Abid R. Takabe W. Kohro T. Ge X. Aburatani H. Hamakubo T. Kodama T. Aird J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Biochem. Biophys. PubMed Scopus Google Scholar, G. Yang D. R. N. PubMed Scopus Google Scholar) as the upstream of 1 putative binding (13Liu D. Jia H. Holmes D.I. Stannard A. Zachary I. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2002-2007Crossref PubMed Scopus (141) Google Scholar, 14Minami T. Horiuchi K. Miura M. Abid R. Takabe W. Kohro T. Ge X. Aburatani H. Hamakubo T. Kodama T. Aird J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Biochem. Biophys. PubMed Scopus Google Scholar, G. Yang D. R. N. PubMed Scopus Google Scholar). and of the upstream region of DSCR1-1L gene showed that this DSCR1-1L promoter luciferase in endothelial of this region to of a family of transcriptional TEF, which is responsible for VEGF-A165-induced DSCR1-1L gene transcription on a of of the putative TEF binding M-CAT site upstream of the DSCR1-1L translation start site of DSCR1-1L promoter induced by a of this M-CAT site can be by this M-CAT can be used to transcriptional of the TEF family of transcriptional M-CAT CAT is a conserved by transcription enhancer family K.J. Genet. PubMed Scopus Google Scholar). The human transcriptional enhancer factor family I. H. Full Text PDF PubMed Scopus Google TEF3 J.J. J.A. I. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, J. D. Genomics. PubMed Scopus Google Scholar, Y. J.A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, M. K. H. Biochem. Biophys. PubMed Scopus Google Scholar, G. N. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google J.J. J.A. I. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, M. K. H. Biochem. Biophys. PubMed Scopus Google and M. K. H. Biochem. Biophys. PubMed Scopus Google Scholar, A. G. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Wu K. Mol. 1999; PubMed Google Scholar). The a conserved binding in which to and muscle-specific M-CAT The of family members has been by a of J. D. Genomics. PubMed Scopus Google Scholar, I. H. Full Text PDF PubMed Scopus Google Scholar, M. K. H. Biochem. Biophys. PubMed Scopus Google Scholar, G. N. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Wu K. Mol. 1999; PubMed Google Scholar, A. L. J.R. Y. J. PubMed Scopus Google Scholar). TEF3, and are expressed in the and to these is expressed in a of the and portion of the and as as the but it is from the data that of the four family members expressed in was to I. R. A. Full Text PDF PubMed Scopus Google Scholar). it was found to the of and J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Y. J.A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Mol. Biol. PubMed Scopus Google Scholar). with knock-out have and in Lawrence G. B. J. PubMed Scopus Google Scholar). TEF3 was from human and to with in and in and J. D. Genomics. PubMed Scopus Google Scholar). TEF3 was also found to be up-regulated in endothelial cells to promoter Wu G. Wu J. J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). TEF3 is expressed in and in muscle-specific gene expression J.J. J.A. I. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). to be in system J.J. J.A. I. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). is expressed in and human gene enhancer and J.J. J.A. I. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, Wu K. Mol. 1999; PubMed Google Scholar). was roles in VEGF-A165 we found for the that it was TEF3, not other family members that is required for the of M-CAT induced by VEGF-A165 and for VEGF-A165-induced DSCR1-1L expression. that TEF3 directly interacted with M-CAT in vitro and in vivo. The function of other family members in HUVEC to be data that inhibited the expression of TEF3 and DSCR1-1L may be to regulated the expression of TEF3 and regulated the expression of DSCR1-1L we not interacted with DSCR1-1L in not in data even regulated DSCR1-1L it was regulated The other is the of the of the TEF3 gene in and demonstrated to be in cardiac and J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). human of TEF3 was from a J. D. Genomics. PubMed Scopus Google Scholar, B. I. Hum. Mol. Genet. 1995; 4: PubMed Scopus Google Scholar). of human the of expression in and with in the and whereas the was not in the J. D. Genomics. PubMed Scopus Google Scholar). of the of TEF3 a different expression with that in the with low in and and in and whereas TEF3 is in G. N. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). TEF3 to the CAT to the expression of muscle-specific and it muscle-specific for transcriptional J. T. T. PubMed Scopus Google Scholar). of TEF3 that it to be expressed in cells human vascular endothelial cells and B. T.J. Davies Y. B. Y. T. PubMed Scopus Google Scholar). and are expressed is induced by in human vascular endothelial cells B. T.J. Davies Y. B. Y. T. PubMed Scopus Google Scholar). and induced promoter with and with deletion promoter showed that required the of for and that the was not for Wu G. Wu J. J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). to that TEF3 was in the of We TEF3 isoform 1 and TEF3 isoform from HUVEC and in that TEF3 isoform 1, not TEF3 isoform 3, regulated the expression of we have a novel transcriptional mechanism that VEGF-A165-induced DSCR1-1L in which VEGF-A165 induced of TEF3 with the M-CAT of DSCR1-1L on that DSCR1-1L may as a we that TEF3 may also function to to the by which VEGF-A165 the of TEF3 and also to the of and other TEF3 in tumor angiogenesis.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: